DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/01ca01/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceuticals and Healthcare Report Q1 2012" report to their offering.
Business Monitor International's Sweden Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Sweden's pharmaceuticals and healthcare industry.
Sweden's pharmaceutical market is expected to grow weakly over the coming years as the government's attempts to contain health care costs focus on pharmaceutical expenditure. Having said that, a high quality and equitable health care system and stable regulatory environment will ensure that it remains attractive to innovative drugmakers both as a market and as a base for R&D activities.
Headline Expenditure Projections
- Pharmaceuticals: SEK30.57bn (US$3.85bn) in 2010 to SEK30.30bn (US4.73$bn) in 2011; 0.9%% in local currency terms and +23.0% in US dollar terms.
- Healthcare: SEK308.03bn (US$40.75bn) in 2010 to SEK317.27bn (US$49.57bn) in 2011; +3.0% in local currency terms and +21.6% in US dollar terms.
- Medical devices: SEK19.28bn (US$2.43bn) in 2010 to SEK20.04bn (US$3.13bn) in 2011; +3.9% in local currency terms and +29.0% in US dollar terms.
Key Trends And Developments
- In September 2011, Roche was awarded the first public tender to screen women for cervical cancer with its human HPV diagnostic test. Pilot screening will commence in November prior to nationwide roll-out of the programme. The test is able to identify human HPV DNA from 14 high-risk genital HPV types that are commonly associated with cervical cancer. The test specifically identifies types HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
- In August 2011, Medivir, a Swedish pharmaceutical company specialising in infectious diseases, has agreed to sell its generics business, BMM Pharma, to fellow Swedish firm Bluefish Pharmaceuticals. Bluefish is to acquire BBM Pharma for US$4mn plus inventories, which are valued at US$1.8mn. BBM Pharma employees will not transfer as part of the acquisition.
Companies Mentioned:
- Meda
- Swedish Orphan Biovitrum
For more information visit http://www.researchandmarkets.com/research/01ca01/sweden_pharmaceuti